Both in Pharmaceuticals
Relmada Therapeutics vs Gyre Therapeutics
Over the past year RLMD returned +50.5% and GYRE returned −38.8%; their daily moves had a correlation of 0.20.
RLMD +50.5% GYRE −38.8%Growth of $1, one year, split-adjusted
| Metric | RLMD | GYRE |
|---|---|---|
| Price | $4.17 | $4.44 |
| Market cap | $444.8M | $470.8M |
| Today | −2.34% | 0.00% |
| 1 month | +27.1% | −37.3% |
| 6 months | −46.9% | −44.8% |
| Year to date | −13.7% | −37.1% |
| 1 year | +89.5% | −39.7% |
| Revenue growth (YoY) | — | −2.1% |
| Gross margin | — | 92.4% |
| Net margin | — | −40.1% |
| P/E (TTM) | — | — |
| Price / sales | — | 3.9× |
| Net cash | $217.7M | $74.8M |
| Dividend yield | — | — |
| Volatility (60d) | 60.0% | 88.3% |
| Short % of float | 14.0% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).